Novartis, “We have no plan to compensate for the difference of Galvusmet’s dropped price”

As the company announced it has no plan to compensate the difference of the decreased drug price of Galvusmet whose upper limit price will be dropped from the 1^st of December, the distribution industry has made a strong opposition.

A company which jointly sell the Novartis’ DPP-4 inhibitor antidiabetic ‘Galvusmet,’ OnlinePharm gave a notice that there will be no compensation for the difference...